Farther Finance Advisors LLC Cuts Position in Repligen Co. (NASDAQ:RGEN)

Farther Finance Advisors LLC reduced its position in shares of Repligen Co. (NASDAQ:RGEN) by 80.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 259 shares of the biotechnology company’s stock after selling 1,060 shares during the period. Farther Finance Advisors LLC’s holdings in Repligen were worth $39,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of RGEN. Thrivent Financial for Lutherans boosted its holdings in Repligen by 240.5% during the 2nd quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock valued at $75,866,000 after acquiring an additional 425,061 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Repligen by 21.0% in the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after purchasing an additional 237,884 shares during the period. Conestoga Capital Advisors LLC increased its stake in Repligen by 26.7% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock worth $119,363,000 after buying an additional 199,322 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Repligen by 39.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock worth $54,149,000 after buying an additional 121,305 shares in the last quarter. Finally, New York State Common Retirement Fund lifted its holdings in Repligen by 14.4% during the 3rd quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company’s stock worth $84,387,000 after buying an additional 71,274 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

RGEN has been the subject of several research reports. Royal Bank of Canada restated an “outperform” rating and issued a $205.00 price target on shares of Repligen in a research note on Thursday, September 26th. Wells Fargo & Company initiated coverage on Repligen in a report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price target on the stock. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Wednesday. UBS Group cut their target price on shares of Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. Finally, Benchmark reiterated a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $190.25.

Insider Transactions at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. This trade represents a 13.70 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 1.20% of the company’s stock.

Repligen Stock Performance

Shares of RGEN opened at $142.43 on Friday. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $211.13. The stock has a 50 day moving average price of $141.59 and a 200 day moving average price of $144.78. The company has a market capitalization of $7.98 billion, a price-to-earnings ratio of -389.94, a price-to-earnings-growth ratio of 4.27 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The firm had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. During the same period last year, the firm posted $0.23 EPS. The company’s revenue was up 9.7% on a year-over-year basis. Research analysts predict that Repligen Co. will post 1.45 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.